Shaji Kumar, ASH 2022: Key clinical trials in smoldering myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of three key clinical trials presented at ASH 2022 in the field of smoldering myeloma, an area of great interest and opportunity to improve patient overall survival.
Abstract 3253: Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study (1:16-01:35)
Abstract 118: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD) (01:40-02:50)
Abstract 757: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial (02:50-04:30)
Disclosures: Shaji Kumar discloses research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 64th ASH Annual Meeting & Exposition
